Soligenix (NASDAQ: SNGX) warned on Nasdaq equity listing compliance
Rhea-AI Filing Summary
Soligenix, Inc. reported that it received a notice from Nasdaq on August 15, 2025 stating the company no longer meets the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market. In its Form 10-Q for the quarter ended June 30, 2025, Soligenix reported stockholders’ equity of $1,828,951, below this threshold, although this figure does not include gross proceeds of approximately $1,439,300 from sales under its At-The-Market facility on July 1, 2025.
The company also does not satisfy Nasdaq’s alternative continued listing standards based on market value or net income. The notice does not immediately affect trading, and the stock continues to trade on Nasdaq under the symbol SNGX. Soligenix has 45 calendar days, until September 29, 2025, to submit a plan to regain compliance, and Nasdaq may grant up to 180 days from the notice date to evidence compliance. If the plan is not accepted or compliance is not regained, the company’s common stock could become subject to delisting, with the possibility of an appeal to a Nasdaq Hearings Panel.
Positive
- None.
Negative
- Nasdaq noncompliance and delisting risk: Soligenix’s reported stockholders’ equity of $1,828,951 is below Nasdaq’s $2,500,000 requirement, and the company also fails alternative listing standards, creating a defined timeline and explicit risk that its common stock could ultimately be delisted if compliance is not regained.
Insights
Nasdaq equity deficiency raises near-term listing and financing risk.
Soligenix has been notified by Nasdaq that its stockholders’ equity of $1,828,951 as of June 30, 2025 is below the $2,500,000 requirement for The Nasdaq Capital Market. The company also does not meet the alternative continued listing standards based on a $35,000,000 market value of listed securities or $500,000 in net income from continuing operations over specified periods. This combination signals a relatively weak capital position under Nasdaq’s rules.
The notice does not immediately affect trading, and the common stock continues on Nasdaq under the symbol SNGX. Soligenix notes that its June 30 equity figure excludes approximately $1,439,300 of gross proceeds from At-The-Market sales on July 1, 2025, which may improve reported equity in future filings. However, the company explicitly cautions there is no assurance its compliance plan will be accepted or that it will successfully regain compliance.
Key procedural dates are a 45-day window, until September 29, 2025, to submit a plan, and a potential extension of up to 180 days from the August 15, 2025 notice to demonstrate compliance. If Soligenix fails to satisfy Nasdaq’s requirements within these parameters, its common stock could become subject to delisting, though Nasdaq rules would allow an appeal to a Hearings Panel, which would stay any suspension or delisting action during the hearing process and any additional extension period granted.
8-K Event Classification
FAQ
Why did Soligenix (SNGX) receive a Nasdaq deficiency notice?
Soligenix received a notice from Nasdaq because its stockholders’ equity reported in its Form 10-Q for the quarter ended June 30, 2025 was $1,828,951, below the $2,500,000 minimum required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1).
What are Nasdaq’s continued listing requirements that Soligenix does not meet?
Nasdaq Listing Rule 5550(b)(1) requires stockholders’ equity of at least $2,500,000. Soligenix also does not meet the alternative standards of a market value of listed securities of at least $35,000,000, or net income of $500,000 from continuing operations in the most recently completed fiscal year or in two of the three most recently completed fiscal years.
Does the Nasdaq notice immediately affect trading in Soligenix (SNGX) stock?
No. The company states that the notice has no immediate effect on the listing of its common stock, and the shares continue to trade on The Nasdaq Capital Market under the symbol SNGX, subject to compliance with other continued listing requirements.
What deadlines has Nasdaq given Soligenix to regain compliance?
Soligenix has 45 calendar days from the August 15, 2025 notice, or until September 29, 2025, to submit a plan to regain compliance. If Nasdaq accepts the plan, it may grant an extension of up to 180 calendar days from the date of the notice for Soligenix to evidence compliance.
How does Soligenix’s At-The-Market (ATM) activity factor into its equity position?
The company notes that the $1,828,951 stockholders’ equity reported as of June 30, 2025 does not reflect sales under its At-The-Market facility on July 1, 2025, which generated approximately $1,439,300 in total gross proceeds. These proceeds could affect equity levels reflected in subsequent reporting periods.
What could happen if Soligenix cannot regain Nasdaq listing compliance?
If Soligenix’s plan is not accepted, or if accepted but the company does not regain compliance within up to 180 days from the date of Nasdaq’s letter, or if it fails another Nasdaq requirement, Nasdaq could notify the company that its common stock will become subject to delisting. Under Nasdaq rules, Soligenix could then request a hearing before a Nasdaq Hearings Panel, which would stay any suspension or delisting during the hearing process and any additional extension period granted.